Ono Pharmaceutical expands collaboration with Congruence Therapeutics using Revenir™ platform for neurology & immunology small molecules. Details on options, milestones, royalties
Written By: Karthik Teja, PharmD
Reviewed By: Pharmacally Editorial Team
Osaka-based Ono Pharmaceutical Co., Ltd. has broadened its partnership with Canadian Congruence Therapeutics, shifting focus from oncology to neurology and immunology in a bid to uncover novel small molecule modulators.
The expansion builds on a December 2024 option-type collaboration where Congruence’s Revenir™ platform generated oncology candidates. Under the new agreement, Congruence will target multiple protein targets in neurology and immunology, producing small molecule drug candidates. Ono secures exclusive worldwide options to develop, manufacture, and commercialize selected candidates.
Financial terms include an upfront payment, research funding, progress-based milestones, and tiered royalties on net sales post-launch.
Seishi Katsumata, Ono’s Corporate Officer and Executive Director of Discovery & Research, highlighted the platform’s momentum: “Congruence’s advanced computational discovery engine is attracting growing global attention with its lead program entering clinical development. We are honored that our ongoing collaboration… is expanding beyond oncology to other priority areas.”
Sharath Hegde, PhD, Congruence’s Chief Scientific Officer, echoed the enthusiasm: “The expansion is a testament to the significant contributions we have made in our existing collaboration as well as the trust and confidence we continue to build with Ono. We look forward to leveraging the complementary strengths of both organizations to advance important research for the benefit of patients.”
Revenir™ Platform Powers Precision Drug Design
Congruence’s proprietary Revenir™ platform analyzes dynamic biophysical changes in proteins across functional states. It scans surface features and biophysical descriptors from protein conformers to predict small molecule modulation of physiologic states. This approach fuels Congruence’s pipeline of first-in-class and best-in-class candidates for genetically validated targets in high-unmet-need diseases, enabling scalable drug discovery.
The deal underscores Ono’s strategy to tap computational tools for faster innovation in neurology and immunology, areas common with unmet needs like neurodegenerative disorders and autoimmune conditions. As Revenir™-derived programs advance such as Congruence’s lead in clinical development, this partnership could accelerate novel therapies to patients.
Reference
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology, 03 March 2026, Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology | ONO CORPORATE
About Writer
Karthik Teja, PharmD
He is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.